Gyre Therapeutics chairman Ying Luo resigns; Ping Zhang appointed as lead independent director

GYRE THERAPEUTICS, INC.

Ying Luo resigned as Chairman and Board member (eff. Dec 31, 2024) to focus on other responsibilities at GNI Group Ltd.
Ping Zhang appointed Class I director, lead independent director, and Nominating Committee member (eff. Jan 5, 2025).
Songjiang Ma appointed Chairman of Gyre Pharmaceuticals Board (eff. Jan 6, 2025).
Zhang is Managing Partner of String Capital and serves on the boards of GNI and Asian Star Co.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ping Zhang

Class I director and lead independent director

GYRE · GYRE THERAPEUTICS, INC.

Effective: 2025-01-05
Filed: January 6, 2025, 6:59 PM ET

On January 5, 2025, the Board appointed Ping Zhang as a Class I director of the Company. Mr. Zhang was also appointed as the lead independent director of the Board and a member of the Nominating Committee.

Departed

Ying Luo

Chairman

GYRE · GYRE THERAPEUTICS, INC.

Effective: 2024-12-31
Filed: January 6, 2025, 6:59 PM ET

On December 31, 2024, Ying Luo, Ph. D. resigned as Chairman and a member of the board of directors (the “Board”) of Gyre Therapeutics, Inc. (the “Company”), as chair and a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”) and as Chairman and a member of the board of directors of Gyre Pharmaceuticals Co., Ltd. (the “Gyre Pharmaceuticals Board”), the Company’s majority indirectly owned subsidiary (“Gyre Pharmaceuticals”), effective immediately, due to his need to focus on other responsibilities at GNI Group Ltd.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ping Zhang was appointed as Class I director and lead independent director at GYRE THERAPEUTICS, INC..

Action: appointed
Role: Class I director and lead independent director

Exact text from the filing

On January 5, 2025, the Board appointed Ping Zhang as a Class I director of the Company. Mr. Zhang was also appointed as the lead independent director of the Board and a member of the Nominating Committee.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ying Luo resigned as Chairman at GYRE THERAPEUTICS, INC..

Action: resigned
Role: Chairman

Exact text from the filing

On December 31, 2024, Ying Luo, Ph. D. resigned as Chairman and a member of the board of directors (the “Board”) of Gyre Therapeutics, Inc. (the “Company”), as chair and a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”) and as Chairman and a member of the board of directors of Gyre Pharmaceuticals Co., Ltd. (the “Gyre Pharmaceuticals Board”), the Company’s majority indirectly owned subsidiary (“Gyre Pharmaceuticals”), effective immediately, due to his need to focus on other responsibilities at GNI Group Ltd.

View on SEC.gov

GYRE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-25-000292

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.